Chartwell Investment Partners’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Chartwell Investment Partners’s Portfolio ODT Stock Details ODT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-12,771	Closed	-$541K	–	441
2020 Q2	$541K	Sell	12,771 -4,657	-27%	-$151K	0.02%	375
2020 Q1	$481K	Buy	17,428 +2,007	+13%	+$58.5K	0.02%	366
2019 Q4	$500K	Sell	15,421 -15,122	-50%	-$469K	0.02%	385
2019 Q3	$795K	Hold	30,543	–	–	0.03%	374
2019 Q2	$1.12M	Buy	30,543 +1,782	+6%	+$42.7K	0.04%	373
2019 Q1	$636K	Buy	28,761 +389	+1%	+$6.8K	0.02%	405
2018 Q4	$399K	Sell	28,372 -422	-1%	-$6.57K	0.01%	430
2018 Q3	$559K	Buy	28,794 +40	+0.1%	+$816	0.02%	455
2018 Q2	$635K	Sell	28,754 -1,087	-4%	-$25.3K	0.02%	467
2018 Q1	$632K	Sell	29,841 -377	-1%	-$8.89K	0.02%	393
2017 Q4	$755K	Buy	+30,218	New	+$714K	0.03%	395

Other funds holding ODT

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Chartwell Investment Partners's ODT Position: Q3 2020 in Review

Chartwell Investment Partners sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q3 2020, closing a stake of 12,771 shares — an estimated $541K sold.

Chartwell Investment Partners first reported a position in ODT in Q4 2017 and held it in 11 quarters. The position peaked at $1.12M in Q2 2019. 89 funds tracked by Wall St. Rank hold ODT as of Q3 2020.

Chartwell Investment Partners reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
Chartwell Investment Partners sold 12,771 Odonate Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $541K.
Chartwell Investment Partners first reported a position in Odonate Therapeutics, Inc. Common Stock in Q4 2017 and held it in 11 quarters.
Chartwell Investment Partners's Odonate Therapeutics, Inc. Common Stock position peaked at $1.12M in Q2 2019.
89 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Chartwell Investment Partners's 13F filing for Q3 2020, filed 16 Nov 2020.